Study on Mouth Cancer Patients

STATUS OF HERBOMINERAL DRUG LAS02 IN MOUTH CANCER PRE AND POST TREATED PATIENTS

SUMMARY OF THE STUDY

The aim of this study was to measured the efficacy of new herbomineral drug of LAS02 in Mouth cancer patients who admitted in Lavanya Ayurvedic Hospital & Research Centre For Cancer and AIDS. The study was conducted after getting ethical clearance. Total 43 patients were enrolled in Lavanaya hospital. These patients were suffering only from Mouth cancer not any other diseases. All patients having medication ayuredic herbomineral drug of LAS02 for more than one month treatment. After obtaining prior consent form these patients, venous blood samples was collected from the subjects before and after treatment with herbomineral drug of LAS02 and measured the hematological and biochemical examinations along with Mouth cancer in tumor size.

A 11.33% percentage level reduction in tumor size(mm) was found to be in Mouth cancer patients as compared to before treated patients (n=43) There was percentage level 1.81% decreased ESR levels in patients after treatment with LAS02 drug more than one month as compared with before treatment. A 22.58%, 19.42%, 11.53%, 18.66% percentage level reduction of hepatic enzymes (SGOT, SGPT, ALP and LDH) in patients after treatment(post treated) with drug LAS02.

CLINICAL SUBJECTS

The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 43 Mouth cancer patients with age (30-80 years) in Lavanya Ayurvedic Hospital and Research Center. These patients were only suffering from Mouth Cancer not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 Capsule under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with pre and post treated patients.

HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS

All hematological and biochemistry parameters should be determined hemoglobin (Hb), lactate dehydragenase (LDH) alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) parameters were measured by fully automatic cell counter and clinical chemistry analyzer.

LACTATE DEHYDROGENASE ACTIVITY (LDH)

LDH activity was measured by kit according to protocol provided by supplier (Transasia biomedical). The activity was expressed as an IU/ml.

STATISTICAL ANALYSIS

Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treated patients with LAS02 drug in Mouth cancer.

RESULTS

Status on Tumor size(mm)

Reduction of percentage level was found to be 11.53% in total tumor size (mm) patient post treated group in comparison to patient pre treated group.

Effect on ESR level

The percentage level of ESR was found to be 1.81% decreased in the patients after treatment with LAS02 drug in comparison to pre treatment.

Effect on hemoglobin

There were slightly increased Hb(%), hematocrit and RBC levels in patient treated group as compared with patient pre treated group.

Effect on Lactate dehydrogenase (LDH) and Alkaline phosphatase ( ALP) activities

There were significant 18.66% and 11.53% reduction of LDH and ALP enzyme activities in patients post treated group in comparison to patient pre treated group.